BioSpace News Archive

Biovica announces that it has received Laboratory Accreditation from the College of American Pathologists for its Clinical Laboratory Improvement Amendments -certified laboratory in San Diego, California.

BioNTech SE will present data across its oncology pipeline, covering multiple solid tumor types and novel mechanisms of action, at the European Society for Molecular Oncology Congress 2023 in Madrid, Spain from October 20-24, 2023.

Revvity, Inc. and Element Biosciences, Inc., a developer of the AVITI™ System, an innovative and emerging genomic sequencing platform, announced a collaboration to introduce workflow solutions that save time and effort required for genomic analysis of samples.

Abbisko Therapeutics Co., Ltd. announced that the results of the company’s two preclinical studies published at the 35th International Molecular Targets and Cancer Treatment Conference be held in Boston, U.S. These two research results respectively demonstrate the latest preclinical research progress of the next generation of PRMT5*MTA inhibitors and small molecule brain penetrant PD-L1 inhibitors in Abbisko’s pipeline.

Immunic, Inc. announced the presentation of data from the company’s phase 2 CALDOSE-1 trial of vidofludimus calcium in an oral presentation at the United European Gastroenterology Week 2023, taking place October 14-17 in Copenhagen.

SwanBio Therapeutics announced the addition of two industry veterans to the company’s leadership team: John Tsai, MD as executive chair, and Christopher “Topher” Brooke as chief operating officer.

BD announced the most recent results of a recycling pilot to manage discarded syringes and needles that led to 40,000 pounds of medical waste being recycled and diverted from disposal.

NanoViricides, Inc., reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2023 with the Securities and Exchange Commission on Friday, October 13, 2023.

BerGenBio ASA announced that a poster and an oral presentation summarizing completed studies with its lead product candidate bemcentinib will be presented at the upcoming European Society of Clinical Oncologists Annual Meeting 2023, to be held October 20-24 in Madrid.

CANbridge Pharmaceuticals Inc. announced that the core part of the ongoing CAN103 Phase 2 trial, in treatment-naïve patients aged 12 or above with Gaucher disease Types I and III, has reached full enrollment.